S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
NASDAQ:AXDX

Accelerate Diagnostics Stock Forecast, Price & News

$10.01
-0.28 (-2.72 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.82
Now: $10.01
$10.59
50-Day Range
$8.51
MA: $11.01
$15.00
52-Week Range
$4.53
Now: $10.01
$19.11
Volume245,200 shs
Average Volume815,668 shs
Market Capitalization$595.28 million
P/E RatioN/A
Dividend YieldN/A
Beta2.35
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Accelerate Diagnostics logo

Headlines

Top 10 Short Positions Held By Hedge Funds Today
January 29, 2021 |  finance.yahoo.com
Is AXDX A Good Stock To Buy Now?
December 14, 2020 |  finance.yahoo.com
Accelerate Diagnostics, Inc. to Host Earnings Call
November 5, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXDX
CUSIPN/A
Phone520-365-3100
Employees275
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.30 million
Book Value($0.14) per share

Profitability

Net Income$-84,310,000.00
Net Margins-697.50%

Miscellaneous

Market Cap$595.28 million
Next Earnings Date5/6/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

137th out of 1,960 stocks

Analytical Instruments Industry

3rd out of 29 stocks

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
$10.01
-0.28 (-2.72 %)
(As of 02/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for AXDX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Accelerate Diagnostics?

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Accelerate Diagnostics?

Accelerate Diagnostics saw a drop in short interest in the month of January. As of January 29th, there was short interest totaling 10,710,000 shares, a drop of 19.9% from the January 14th total of 13,370,000 shares. Based on an average trading volume of 590,400 shares, the short-interest ratio is currently 18.1 days. Currently, 34.8% of the shares of the stock are short sold.
View Accelerate Diagnostics' Short Interest
.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Accelerate Diagnostics
.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings data on Monday, February, 22nd. The medical research company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.32) by $0.01.
View Accelerate Diagnostics' earnings history
.

How has Accelerate Diagnostics' stock price been impacted by Coronavirus (COVID-19)?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AXDX shares have decreased by 5.7% and is now trading at $10.01.
View which stocks have been most impacted by COVID-19
.

What guidance has Accelerate Diagnostics issued on next quarter's earnings?

Accelerate Diagnostics issued an update on its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $3.1-3.1 million, compared to the consensus revenue estimate of $4.41 million.

What price target have analysts set for AXDX?

3 brokers have issued 12 month price objectives for Accelerate Diagnostics' stock. Their forecasts range from $15.00 to $20.00. On average, they expect Accelerate Diagnostics' share price to reach $17.50 in the next twelve months. This suggests a possible upside of 74.8% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:
  • Mr. Jack Phillips, CEO, Pres & Director (Age 55, Pay $289.43k)
  • Mr. Steve Reichling, CFO, Chief Accounting Officer & Sec. (Age 43, Pay $340k)
  • Mr. Lawrence Mehren, Advisor (Age 55, Pay $500k)
  • Mr. Ron Price, Chief Commercial Officer of Americas (Age 57, Pay $240k)
  • Laura Pierson, Investor Relations Officer
  • Mr. Michael Bridge, Sr. VP & Gen. Counsel
  • Ms. Gretchen Strohminger, Sr. VP and Head of HR & Culture
  • Ms. Constance Bridges, Sr. VP and Head of Regulatory & Quality
  • Mr. Cherif Bousselham, Sr. VP & Head of Sales - EMEA
  • Ms. Laura Costa, Sr. VP & Head of Global Customer Support

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), MagnaChip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (3.88%), Credit Suisse AG (2.97%), Chicago Capital LLC (2.82%), Griffin Asset Management Inc. (2.58%), Cannell Peter B & Co. Inc. (1.87%) and Baird Financial Group Inc. (1.64%). Company insiders that own Accelerate Diagnostics stock include Jack W Schuler, Romney Humphries and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics
.

Which major investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Blair William & Co. IL, Barclays PLC, Trellus Management Company LLC, Bank of New York Mellon Corp, Cutter & CO Brokerage Inc., New York State Common Retirement Fund, and Cannell Peter B & Co. Inc.. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Romney Humphries, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or view top insider-selling stocks.

Which major investors are buying Accelerate Diagnostics stock?

AXDX stock was bought by a variety of institutional investors in the last quarter, including Credit Suisse AG, Renaissance Technologies LLC, BlackRock Inc., GSA Capital Partners LLP, Tudor Investment Corp Et Al, Squarepoint Ops LLC, Nuveen Asset Management LLC, and Allworth Financial LP. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $10.01.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $595.28 million and generates $9.30 million in revenue each year. The medical research company earns $-84,310,000.00 in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 275 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Where are Accelerate Diagnostics' headquarters?

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at 520-365-3100 or via email at [email protected]


This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.